Itoco Inc. (ITMC)
USD 0.01
(177.78%)
USD 0.01
(177.78%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2022 | 1.65 Million USD | 60.67% |
| 2021 | 1.02 Million USD | -40.96% |
| 2020 | 1.74 Million USD | -18.65% |
| 2019 | 2.14 Million USD | 121.63% |
| 2018 | 966.71 Thousand USD | -51.25% |
| 2017 | 1.98 Million USD | 647.95% |
| 2016 | 265.13 Thousand USD | -38.18% |
| 2015 | 428.91 Thousand USD | 0.0% |
| 2013 | 4.50 USD | 0.0% |
| 2009 | 6.61 Million USD | 0.0% |
| 2008 | - USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 Q1 | 1.84 Million USD | 11.52% |
| 2023 Q2 | 2 Million USD | 8.69% |
| 2023 Q3 | 2.16 Million USD | 8.28% |
| 2022 Q1 | 1.82 Million USD | 11.11% |
| 2022 Q3 | 1.56 Million USD | -19.91% |
| 2022 FY | 1.65 Million USD | 60.67% |
| 2022 Q4 | 1.65 Million USD | 5.53% |
| 2022 Q2 | 1.95 Million USD | 7.12% |
| 2021 Q1 | 2.22 Million USD | 0.0% |
| 2021 FY | 1.02 Million USD | -40.96% |
| 2021 Q4 | 1.64 Million USD | -34.58% |
| 2021 Q3 | 2.51 Million USD | 9.74% |
| 2021 Q2 | 2.28 Million USD | 2.72% |
| 2020 FY | 1.74 Million USD | -18.65% |
| 2019 FY | 2.14 Million USD | 121.63% |
| 2018 FY | 966.71 Thousand USD | -51.25% |
| 2017 FY | 1.98 Million USD | 647.95% |
| 2016 FY | 265.13 Thousand USD | -38.18% |
| 2015 FY | 428.91 Thousand USD | 0.0% |
| 2013 FY | 4.50 USD | 0.0% |
| 2010 Q2 | 5.81 Million USD | -14.66% |
| 2010 Q3 | 5.48 Million USD | -5.65% |
| 2010 Q1 | 6.8 Million USD | 2.93% |
| 2009 FY | 6.61 Million USD | 0.0% |
| 2009 Q4 | 6.61 Million USD | 13.64% |
| 2009 Q3 | 5.82 Million USD | 1687307.25% |
| 2009 Q2 | 345.00 USD | 1.17% |
| 2009 Q1 | 341.00 USD | 0.0% |
| 2008 Q1 | - USD | 0.0% |
| 2008 Q2 | - USD | 0.0% |
| 2008 Q4 | - USD | 0.0% |
| 2008 FY | - USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -5926.14% |
| Arch Therapeutics, Inc. | 9.46 Million USD | 82.536% |
| Evofem Biosciences, Inc. | 72.47 Million USD | 97.719% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | -104.397% |
| Rebus Holdings, Inc. | 5.24 Million USD | 68.463% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | 97.199% |
| Qrons Inc. | 1.48 Million USD | -11.046% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 1.22 Million USD | -34.818% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | 97.793% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | -3598.655% |
| Skye Bioscience, Inc. | 14.07 Million USD | 88.252% |
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | 96.899% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | 82.747% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | -292.143% |
| SQZ Biotechnologies Company | 50.03 Million USD | 96.696% |
| Intellipharmaceutics International Inc. | 12 Million USD | 86.234% |
| Propanc Biopharma, Inc. | 3.85 Million USD | 57.077% |
| Mesoblast Limited | 188.44 Million USD | 99.123% |
| Marizyme, Inc. | 26.67 Million USD | 93.803% |
| Genus plc | 485 Million USD | 99.659% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | 71.705% |
| Pharming Group N.V. | 244.07 Million USD | 99.323% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | 17.759% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | 34.303% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | 56.496% |
| ContraFect Corporation | 32.53 Million USD | 94.918% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | 16.563% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | 56.81% |
| IMV Inc. | 37.93 Million USD | 95.642% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | 85.964% |
| MultiCell Technologies, Inc. | 1617.67 USD | -102093.34% |
| ONE Bio Corp. | 27.49 Million USD | 93.988% |
| Accustem Sciences Inc. | 1.07 Million USD | -53.177% |
| RVL Pharmaceuticals plc | 77.41 Million USD | 97.865% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 2.11 Million USD | 21.839% |
| Q BioMed Inc. | 8.13 Million USD | 79.673% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | 98.007% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | 67.875% |
| Biomind Labs Inc. | 1.49 Million USD | -10.312% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | 98.608% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | 81.717% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | 91.017% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | -15.294% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | -1063.413% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | -721.989% |
| Curative Biotechnology, Inc. | 5.74 Million USD | 71.229% |
| GB Sciences, Inc. | 5.41 Million USD | 69.485% |
| Alpha Cognition Inc. | 7.16 Million USD | 76.927% |
| HST Global, Inc. | 593.59 Thousand USD | -178.499% |
| CSL Limited | 18.62 Billion USD | 99.991% |
| Wesana Health Holdings Inc. | 1.25 Million USD | -31.287% |
| Halberd Corporation | 728.71 Thousand USD | -126.857% |
| Enzolytics Inc. | 365.26 Million USD | 99.547% |
| Agentix Corp. | 2.51 Million USD | 34.152% |
| Resverlogix Corp. | 67.39 Million USD | 97.547% |
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | -97.101% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 444.95 Million USD | 99.628% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | 3.55% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | 93.32% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | 86.112% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | 54.896% |
| AVAX Technologies, Inc. | 3.99 Million USD | 58.606% |
| Zenith Capital Corp. | 27.56 Thousand USD | -5896.413% |
| Genscript Biotech Corporation | 1.32 Billion USD | 99.875% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | -592.698% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | 55.731% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | -142.813% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | 39.035% |
| Kadimastem Ltd | 3.5 Million USD | 52.833% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | -2370.007% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 50.26 Million USD | 96.711% |
| BioStem Technologies, Inc. | 15.9 Million USD | 89.606% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 464.69 Thousand USD | -255.747% |
| LadRx Corporation | 2.2 Million USD | 24.875% |
| Cell Source, Inc. | 15.8 Million USD | 89.541% |
| Regen BioPharma, Inc. | 5.45 Million USD | 69.709% |
| Regen BioPharma, Inc. | 5.45 Million USD | 69.709% |
| NovAccess Global Inc. | 7.86 Million USD | 78.97% |
| Affymax, Inc. | 8.87 Million USD | 81.365% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | 19.42% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | 72.671% |
| Mobile Lads Corp. | 1.31 Million USD | -25.859% |
| CytoDyn Inc. | 127.89 Million USD | 98.707% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | -3855.001% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | -5.54% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | 85.033% |
| SYBLEU INC | 681.41 Thousand USD | -142.606% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | 72.908% |
| International Stem Cell Corporation | 5.27 Million USD | 68.673% |
| Bioxytran, Inc. | 3.24 Million USD | 49.126% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | -164.162% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | 64.195% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | 95.968% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | 92.575% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | 18.379% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | 69.822% |
| Neutra Corp. | 973.52 Thousand USD | -69.81% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | 94.302% |
| PureTech Health plc | 125.58 Million USD | 98.684% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | 56.0% |
| IXICO plc | 1.9 Million USD | 13.005% |
| IntelGenx Technologies Corp. | 20.52 Million USD | 91.947% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 98.4% |
| CSL Limited | 18.62 Billion USD | 99.991% |
| Cellectis S.A. | 249.36 Million USD | 99.337% |